Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update

By Dr. Matthew Watson

– Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis –

View original post here:
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy... - May 17th, 2024
Thrive Bioscience Welcomes Todd Lewis as Chief Commercial Officer - May 17th, 2024
Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024 - May 17th, 2024
Assertio to Participate in AGP Healthcare Conference on May 21 - May 17th, 2024
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH - May 17th, 2024
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives - May 17th, 2024
Digital Utilities Ventures Completes Feed Earth Now Merger - Accelerates Growth of Regenerative Agriculture Movement - May 17th, 2024
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 - May 17th, 2024
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - May 17th, 2024
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference - May 17th, 2024
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with... - May 17th, 2024
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference - May 17th, 2024
BioSyent Releases Financial Results for Q1 2024 - May 17th, 2024
BioSyent Declares Second Quarter 2024 Dividend - May 17th, 2024
Lifecore Biomedical Completes Incremental Liquidity Initiatives - May 17th, 2024
DBV Technologies Announces Results of its 2024 Combined General Meeting - May 17th, 2024
Fortrea Appoints Machelle Sanders to Board of Directors - May 17th, 2024
QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency - May 17th, 2024
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise - May 17th, 2024
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress - May 17th, 2024
Telesis Bio Announces Reverse Stock Split - May 7th, 2024
Shockwave Medical Reports First Quarter 2024 Financial Results - May 7th, 2024
Aileron Therapeutics to Present at Two Upcoming Investor Conferences - May 7th, 2024
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates - May 7th, 2024
Sana Biotechnology to Present at May and June 2024 Investor Conferences - May 7th, 2024
Day One Reports First Quarter 2024 Financial Results and Corporate Progress - May 7th, 2024
Immuneering Recognizes Melanoma Awareness Month - May 7th, 2024
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity - May 7th, 2024
Helio Genomics to Showcase Results from CLiMB Pivotal Trial in an Oral Presentation at the EASL Congress 2024 - May 7th, 2024
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor - May 7th, 2024
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 - May 7th, 2024
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million - May 7th, 2024
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7th, 2024
T2 Biosystems Announces First Quarter 2024 Financial Results - May 7th, 2024
argenx to Present at BofA Securities 2024 Health Care Conference - May 7th, 2024
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update - May 7th, 2024
Sandoz reports first quarter 2024 sales - May 7th, 2024
Memo Therapeutics increases Series C financing to CHF 45 million - May 7th, 2024
Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025 - May 7th, 2024
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 7th, 2024
Medigene AG reports Financial Results and Business Update for Q1 2024 - April 28th, 2024
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024 - April 28th, 2024
Composition of the Nomination Committee of Orion Corporation - April 28th, 2024
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) - April 28th, 2024
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 - April 28th, 2024
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 - April 28th, 2024
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal... - April 28th, 2024
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) - April 28th, 2024
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda - April 28th, 2024
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management - April 28th, 2024
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - April 28th, 2024
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments - April 28th, 2024
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners - April 28th, 2024
BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles - April 28th, 2024
Sino Biological Finalizes the Acquisition of SignalChem Biotech, Strengthening Global Presence and Expanding Product Portfolio - April 28th, 2024
Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update - April 28th, 2024
Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders - April 28th, 2024
Financière de Tubize - Dividend approval - April 28th, 2024
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant... - April 19th, 2024
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces... - April 19th, 2024
Sanara MedTech Inc. Announces $55 Million Debt Facility - April 19th, 2024
Pharming Group announces the placement of €100 million convertible bonds due 2029 - April 19th, 2024
Digital Utilities Ventures Completes Strategic Merger - Paving the Way for Future Growth and Innovation - April 19th, 2024
Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00 - April 19th, 2024
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States - April 19th, 2024
Immix Biopharma on Track to Dose NXC-201 Patients in United States - April 19th, 2024
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. - April 19th, 2024
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine - April 19th, 2024
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET - April 19th, 2024
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s &... - April 19th, 2024
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings - April 19th, 2024
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted... - April 19th, 2024
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - April 19th, 2024
Codexis to Report First Quarter 2024 Financial Results on May 2 - April 19th, 2024
Addex to Present at the Swiss Biotech Day 2024 - April 19th, 2024
Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering - April 19th, 2024
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs - April 19th, 2024
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer - April 19th, 2024

Global News Feed commento

Comments Off | data

December 9th, 2022

About... Dr. Matthew Watson

This author published 5532 posts in this site.

Comments are closed.

Previous post - Next post

Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites